Περίληψη:
We aimed to determine whether Alemtuzumab-induced immune reconstitution affects immunoglobulin and complement levels in the serum of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. IgG4-levels were increased 24-months after treatment initiation compared to baseline levels in twenty-nine patients. Alemtuzumab-treated patients with the highest IgG4-levels were more prone to thyroid-related autoimmune manifestations and specific autoimmune adverse events such as Crohn's disease, Graves' disease, and hemolytic anemia. Compared to baseline, total IgG-levels showed a trend towards reduced levels following two-courses of Alemtuzumab, but no significant change of C3 and/or C4-levels was observed. In conclusion, monitoring of IgG4-levels can serve as a marker for secondary autoimmunity risk in multiple sclerosis patients treated with Alemtuzumab. © 2021 Elsevier B.V.
Συγγραφείς:
Vakrakou, A.G.
Tzanetakos, D.
Evangelopoulos, M.-E.
Fragoulis, G.E.
Kazakou, P.
Lekka, E.
Kafasi, N.
Tzartos, J.S.
Andreadou, E.
Koutsis, G.
Gialafos, E.
Dimitrakopoulos, A.
Zampeli, E.
Rontogianni, D.
Theocharis, S.
Zapanti, E.
Stathopoulos, P.-A.
Anagnostouli, M.
Stefanis, L.
Kilidireas, C.
Λέξεις-κλειδιά:
alemtuzumab; autoantibody; biological marker; complement; immunoglobulin G, adult; blood; etiology; female; Graves disease; human; immune reconstitution; immunology; lymphocyte count; male; multiple sclerosis; neurologic disease; retrospective study; young adult, Adult; Alemtuzumab; Autoantibodies; Autoimmune Diseases of the Nervous System; Biomarkers; Complement System Proteins; Female; Graves Disease; Humans; Immune Reconstitution; Immunoglobulin G; Infections; Lymphocyte Count; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Young Adult
